Filing Details
Contineum Therapeutics, Inc. (NASDAQ:CTNM) filed a Form 8-K with the Securities and Exchange Commission on June 26, 2026, disclosing a material event.
8k filedNASDAQ:CTNM
Contineum Therapeutics, Inc. (CTNM) Reports Material Event to SEC
Filing Details Contineum Therapeutics, Inc. (NASDAQ:CTNM) filed a Form 8-K with the Securities and Exchange Commission on June 26, 2026, disclosing a material event. Market…
Market Context
Contineum Therapeutics, Inc.'s stock currently trades at $14.19 with a market capitalization of $383.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Contineum Therapeutics, Inc.'s stock.
All SEC filings for Contineum Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CTNM Stock Page
Frequently Asked Questions
Where can I read CTNM's SEC filings?
Browse all filings on our CTNM SEC filings page.
What types of SEC filings does Contineum Therapeutics, Inc. file?
Public companies like Contineum Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.